Corteva (CTVA)
NYSEMaterialsAgricultural InputsSnapshot 2026-07-07
$86.77+0.44%
Close 2026-07-07 · 1-day change
Reading CTVA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CTVA free→NYSEMaterialsAgricultural InputsSnapshot 2026-07-07
Reading CTVA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CTVA free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Materials: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 6% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens weak on capital allocation, earnings delivery, margins.
View ManagementExpectations look high — the market is pricing in about 25% growth a year, above the roughly 4% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskCorteva's growth in Crop Protection revenue must continue to justify its current price. Revenue grew 11% year over year, and the last quarter beat expectations. It trades at 36× P/E, above the 24× peer median, indicating it looks expensive. If Corteva cuts guidance on the next call, that could hurt its stock. Peer multiples imply a price about 25% below where it trades. This read is provisional.
Trailing returns as of 2026-07-07. CTVA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 22 analysts currently covering CTVA (as of Jul 2026).
Based on 6 Wall Street analysts offering 12-month price targets for CTVA in the last 4 months.
A consensus fair price across 14 valuation methods, at three horizons. Current price $86.77. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Fertilizers & Agricultural Chemicals — fair value, gap to price, and forward P/E.
Advances: Focus on Crop Protection revenue growth
Joint development enhances Crop Protection revenue growth potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
Current $86.77
The last 12 months of price, then the range of analyst 12-month targets from today’s $86.77.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Enhance Seed segment performance
Enhances Seed segment performance through new product integration.
Advances: Complete planned separation by 2026-Q4
Board announcement supports planned separation by 2026-Q4.
Advances: Complete planned separation by 2026-Q4
Naming board aids in executing crop protection spinoff.
Partnership enhances Crop Protection Revenue Growth potential.
Threatens: Complete planned separation by 2026-Q4
Ceasing production may delay separation plans.
Advances: Focus on Crop Protection Revenue Growth
Investment in eco-friendly products supports revenue growth.
Advances: Focus on Crop Protection Revenue Growth
Acquisition boosts biologicals, enhancing growth potential.